The Next Frontier: Industrializing Cell Therapy Manufacturing

Q&A with Cell Process Development Manager, Sara Morlacchi

Discover the current state and future growth of the cell therapy industry with insights from Sara Morlacchi, an expert in the cell process development field. In her discussion, Morlacchi highlights the barriers of cost and accessibility in cell therapy, while also shedding light on the modular platform used for manufacturing these products. This adaptable platform can cater to various cell types and therapeutic needs. To address challenges in cell therapy manufacturing, new tools and technologies, such as closed automated systems, are needed to minimize contamination and enhance reproducibility. Looking ahead, Morlacchi predicts that allogeneic therapies, automation, gene editing systems, and MSC-derived exosomes will be significant trends in the next few years.

Finding a CDMO partner with experience in cell therapy processes can help sponsor companies by offering flexible service at each level, including specialized technical capabilities, equipment availability, facility design and analytical platforms that can support every stage of the product’s journey. Learn how leveraging platform processes — including flexible processes based on different cell types such as HSCs, T-cells, NK and MSCs either in smaller scales for autologous production or in larger scales for allogeneic batches — can accelerate development timelines and reduce costs on the path to market.